The trial, led by Keith McCrae, MD, of Cleveland Clinic and supported by the National Institutes of Health, was stopped early because of positive results, according to a Sept. 18 news release from the health system.
The randomized, placebo-controlled study enrolled 144 adults with moderate to severe HHT at 11 U.S. medical centers between 2019 and 2023. The participants were then assigned either pomalidomide or a placebo for 24 weeks.
The primary outcome measured was nosebleed severity, while the secondary outcome focused on quality of life specific to HHT. The results showed that pomalidomide treatment improved both nosebleeds and quality of life for patients.
HHT affects more than 1 in 5,000 people worldwide, causing fragile tangled blood vessels that can lead to life-threatening complications, the release said. There are no FDA-approved treatments to treat the disorder long term.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
